期刊文献+

乳腺浸润性导管癌临床病理因素与BRCA_1和BRCA_2表达的相关性分析 被引量:4

乳腺浸润性导管癌临床病理因素与BRCA_1和BRCA_2表达的相关性分析
下载PDF
导出
摘要 目的:探讨乳腺上皮中BRCA1和BRCA2的表达与乳腺浸润性导管癌的临床病理特征的相关性。方法:应用免疫组化S-P法检测BRCA1、BRCA2在33例乳腺浸润性导管癌组和31例乳腺良性病变组的表达情况,并联合ER、PR、CerBb-2的表达,分析它们与乳腺浸润性导管癌患者的年龄、肿块大小、分化程度、淋巴结转移等特征之间的关系。结果:①BRCA1的阳性表达与乳腺浸润性导管癌患者的年龄、分化程度、是否绝经均有显著相关性(P<0.05),与淋巴结转移和肿瘤大小无显著相关性(P>0.05)。BRCA2的阳性表达与乳腺浸润性导管癌患者的年龄、淋巴结转移、肿块大小、是否绝经均有显著相关性(P<0.05),与分化程度无显著相关性(P>0.05)。②BRCA1、BRCA2的表达与CerBb-2的表达均呈显著的负相关(r=-0.355,-0.517,P<0.05)。结论:BRCA1和BRCA2的突变在乳腺浸润性导管癌的发生发展密切相关,主要通过转录途径作用于CerBb-2,BRCA1和BRCA联合CerBb-2可作为评价乳腺癌生物学特性和预后的潜在指标。 The expressions of breast cancer susceptibility genel ( BRCA1 ) and breast cancer susceptibility gene2 (BRCA2 )in breast epithelia are explored. The intrinsic relevance among the expres- sions of BRCA1 and BRCA2, the develop- ment and prognosis in invasive ductal carci- noma of breast are investigated. Methods: The immunohistochemical S- P method wasused to detect the level of BRCA1, BRCAz in 33 cases of breast invasive ductal carci- noma tissue samples and 31 cases of breast benign disease tissue samples. Associating with the expressions of estrogen receptor ( ER), progestogen receptor ( PR), and epi- dermal growth factor receptor2 ( CerBb - 2 ) , an analysis is needed in the relationship be- tween the expressions of ER, PR, CerBb - 2,BRCAI ,BRCA2 and the characters of pa- tients such as the age, the size of tumor, the grade of differentiation, and lymph node me- tastasis. Results:①The positive expression in BRCA1 exhibits an apparent relevance with the characters of patients such as the age, the size of tumor, the grade of differen- tiation, lymph node metastasis, menopausal age( P 〈 0.05 ) ,while it shows little correla- tions to the grade of differentiation ( P 〉 0. 05 ). (~ The expressions of BRCA1 and BRCA2 were negatively correlated to the ex- pression of CerBb - 2 ( r = - 0. 355, or - 0. 517, P 〈 0.05 ). Conclusion : The mutation of BRCAl and BRCA2 takes a key role in the generation of breast invasive ductal carcino- ma,which can be as a reference to detect bi- ological behavior or prognosis in breast car- cinoma.
出处 《中国社区医师(医学专业)》 2013年第6期108-110,共3页
基金 奎屯市2011年度科技项目(项目编号:201122)
关键词 乳腺浸润性导管癌 BRCA1 BRCA2 免疫组织化学 Breast invasive ductal carcino-ma BRCA1 BRCA2 Immunohistochemistry
  • 相关文献

参考文献3

  • 1Singletary SE. Breast cancer management:the road to today [J]. Cancer, 2008,113(7):1844 - 1849.
  • 2Scully R, Ganesan S, Brown M,et al. Location of BRCA1 in human breast and ovarian cancer cells [ J]. Science, 1996,272 : 123 - 126.
  • 3Chen Y, Chen CF, Riley DJ, et al. Aberrant subcellular localization of BRCAt in Breast Cancer[ J]. Science, 1995,270:789 - 791.

同被引文献39

  • 1邹晓,魏涛,宋修岐,薛龙.乳癌相关分子标记物研究进展[J].青岛大学医学院学报,2006,42(2):185-186. 被引量:2
  • 2Kalashnikova EV,Revenko AS,Gemo AT,et al.ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis,acting to drive proliferation and survival of triple negative cells through control of B-Myb and EZH2[J].Cancer Res,2010,70(22):9402-9412.
  • 3KLUK B J, FU Y, FORMOLO T A. Sporadic breast cancer [J]. International Journal of Biological Sciences, 2010,6(5): 513-524.
  • 4VENKITARAMAN A R. Cancer suppression by the chromo- some custodians, BRCA1 and BRCA2 [J]. Science (New York, N.Y.), 2014,343(6178) :1470-1475.
  • 5Chen W, Wang J, Li X, et al. Prognostic significance of BRCAI expression in gastric cancer[J]. Med Oncol,2013,30(1 ):423. 001: 10.1 007/s 12032-0 12-0423-5.
  • 6Chuthapisith S, Eremin JM, El-sheemy M, et al. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy[J]. Surgeon,2006,4( 4 ):211-219.
  • 7Ting NS, Lee WHo The DNA double-strand break response pathway-becorning more BRCAish than ever[J]. DNA Repajr,2004,3(8- 9):935,944. D0I:10.1016/j.dnarep.2004.03.026.
  • 8Mullan PB, Quinn JE, Harkin DP. The role of BRCAI in transcriptional regulation and cell cycle control[J]. Oncogene,2006,25 (43 ):5854-5863. 001: 10. 1038/sj.onc. 1209872.
  • 9Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCAI in the cellular response to chemotherapy[J]. J Natl Cancer Inst,2004,96 (22):1659-1668. 001: 1O.1093/jnci/djh312.
  • 10Byrski TL, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCAl-positive breast cancer patients[J].Breast Cancer Res Treat,2009,115 (2):359-363. 001:10.10071 sI0549-008-0128-9.

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部